Table 1.
Patient characteristics.
| Characteristics | Total n=73 |
|---|---|
| Female n (%) | 46 (63) |
| Never smoker n (%) | 8 (11) |
| Mean age at diagnosis metastatic NSCLC, years (range) | 62.8 (32-84) |
| Molecular subgroup n (%) | |
|
EGFR+
KRAS+ EGFR/KRAS wildtype |
23 (32) 36 (49) 14 (19) |
| Tumor origin n (%) | |
| Lung (primary tumor) Bone Other metastasis |
29 (40) 9 (12) 35 (48) |
| Metastatic disease at diagnosis n (%) | 47 (64) |
| Bone metastases at diagnosis stage IV n (%) | 27 (37) |
| Bone metastases at diagnosis or during course of disease n (%) | 46 (63) |
| SRE n (%)* | 26 (57) |
| Type of SRE n (%)# | |
| Radiotherapy Pathologic fracture Surgery Spinal cord compression |
25 (96) 4 (15) 6 (23) 2 (8) |
| BTA use in all patients n (%)$
Denosumab Bisphosphonate |
9 (12) 1 (1) 8 (11) |
n, number; EGFR+, Epidermal Growth Factor Receptor mutation; KRAS+, Kirsten rat sarcoma mutation; SRE, skeletal related event; BTA, bone targeted agent.
*Percentages were calculated by group of patients with bone metastases.
#Percentages were calculated by subgroup of all pts with SREs (n=26). Some patients experienced more than one SRE.
$Denosumab was used in one patient without bone metastases, all patients who used bisphosphonates had bone metastases.